Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development

  • Steven J. Potts
  • David A. Eberhard
  • Keith A. Wharton, Jr.

Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Keith A. Wharton Jr., Benjamin H. Lee, Pierre Moulin, Dale Mongeon, Rainer Hillenbrand, Arkady Gusev et al.
    Pages 43-63
  3. Patrick Caplazi, Lauri Diehl
    Pages 65-78
  4. Mohamed E. Salama, David A. Eberhard, Steven J. Potts
    Pages 79-85
  5. Steven J. Potts, David A. Eberhard, Mohamed E. Salama
    Pages 87-100
  6. Mohamed E. Salama, Erik Hagendorn, Sherrie L. Perkins, Jeff L. Kutok, A. Etman, Josef T. Prchal et al.
    Pages 117-126
  7. Erik Hagendorn, Christa Whitney-Miller, Aaron Huber, Steven J. Potts
    Pages 141-152
  8. Steven J. Potts, Mirza Peljto, Mahipal Suraneni, Joseph S. Krueger
    Pages 175-182
  9. Mirza Peljto, Joseph S. Krueger, Nicholas D. Landis, G. David Young, Steven J. Potts, Holger Lange
    Pages 183-189
  10. Matthew J. McGinniss, David A. Eberhard, Keith A. Wharton Jr.
    Pages 219-257
  11. Michael D. Lunt, Christa L. Whitney-Miller
    Pages 271-279
  12. Joseph S. Krueger, Holger Lange, G. David Young, Steven J. Potts
    Pages 325-343
  13. Carla Heise, Pierre Brousset, Tommy Fu, David A. Eberhard, Graham W. Slack, Camille Laurent et al.
    Pages 345-358
  14. Joshua C. Black, Mahipal V. Suraneni, Steven J. Potts
    Pages 359-371
  15. Back Matter
    Pages 373-375

About this book


Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development gathers diverse experts to present state of the art guidance and application of histopathology in drug development settings ranging from discovery research to human clinical trials. While many current applications of quantitative histology and molecular pathology in the biopharmaceutical industry are focused on oncology, this volume in addition explores non-oncologic disease areas including nonalcoholic steatohepatitis, arthritis, celiac disease, myeloproliferative disorders, neurology, and wound healing. The authors write from years of experience in diagnostic practice and pharmaceutical drug development, aiming to educate pharmaceutical and academic scientists how to best use tissue to diagnose disease and improve the process of drug development.  As part of the Methods in Pharmacology and Toxicology series, this volume is designed to provide wisdom and examples that others can follow and apply as part of drug development.


Comprehensive and practical, Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development will inform and enlighten both tissue-focused and non-tissue-focused drug development professionals about better use and interpretation of the multidimensional data contained in a tissue biopsy.


Biopharma Companion diagnostics Flagship Biosciences Histology In situ hybridization Initial New Drug Application (IND) Pathology Pharmaceutical research Tissue analysis Tissue biopsy

Editors and affiliations

  • Steven J. Potts
    • 1
  • David A. Eberhard
    • 2
  • Keith A. Wharton, Jr.
    • 3
  1. 1.Flagship Biosciences, LLCWestminsterUSA
  2. 2.University of North CarolinaChapel HillUSA
  3. 3.Novartis Institutes for BioMedical ResearchCambridgeUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media New York 2015
  • Publisher Name Humana Press, New York, NY
  • eBook Packages Springer Protocols
  • Print ISBN 978-1-4939-2680-0
  • Online ISBN 978-1-4939-2681-7
  • Series Print ISSN 1557-2153
  • Series Online ISSN 1940-6053
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods